Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFM 2009-02 pomalidomide plus dexamethasone in relapsed or refractory multiple myeloma
2009-013319-36Phase 2Active
- Sponsor
- CHU de Lille
- Start
- Jul 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pomalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by CHU de Lille. Primary endpoint: Overall response rate. Started Jul 2009; status: active.
02
Drugs
pomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2009-013319-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013319-36.